Pricing
  1. JP-listed companies
  2. TAKARA BIO INC.
  3. Financials
  4. Net income margin (%)

TAKARA BIO INC.【JP:4974】

Market cap
¥138.1B
P/E ratio
-15.3x
Takara Bio develops and manufactures biotechnology products including research reagents, PCR instruments, and gene therapy treatments for universities, research institutions, and companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income margin (%) YoY (%)
Mar 31, 20252.4-30.47%
Mar 31, 20243.5-83.10%
Mar 31, 202320.5-30.17%
Mar 31, 202229.4+41.45%
Mar 31, 202120.8+87.57%
Mar 31, 202011.1+8.15%
Mar 31, 201910.2+41.63%
Mar 31, 20187.2+56.75%
Mar 31, 20174.6+2.41%
Mar 31, 20164.5+21.55%
Mar 31, 20153.7-32.64%
Mar 31, 20145.5-20.39%
Mar 31, 20136.9+142.62%
Mar 31, 20122.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)